Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 61 Neoplasms 35 Colorectal Neoplasms 32 Neoplasm Metastasis 31 Breast Neoplasms 30 Prostatic Neoplasms 26 Pancreatic Neoplasms 26 Ovarian Neoplasms 26 Recurrence 25 Multiple Myeloma 25 Melanoma 23 Squamous Cell Carcinoma of Head and Neck 22 Precursor Cell Lymphoblastic Leukemia-Lymphoma 18 Triple Negative Breast Neoplasms 17 Endometrial Neoplasms 17 Lymphoma, Large B-Cell, Diffuse 16 Lung Neoplasms 16 Glioblastoma 16 Lymphoma, Non-Hodgkin 15 Leukemia, Myeloid, Acute 14 Burkitt Lymphoma 14 Stomach Neoplasms 13 Small Cell Lung Carcinoma 12 Colonic Neoplasms 12 Carcinoma, Renal Cell 12 Uterine Cervical Neoplasms 11 Lymphoma 11 Glioma 11 Gastrointestinal Neoplasms 11 Lymphoma, Follicular 10

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Anal Cancer Metastatic × 30 days × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡